27th week of 2012 patent applcation highlights part 40 |
Patent application number | Title | Published |
20120171171 | Methods and Compositions for In Vitro and In Vivo Chondrogenesis - Aspects of the present invention include methods and compositions related to the production, identification and use of embryonic progenitor cell lines that are capable of undergoing chondrogenesis. A number of exemplary chondrogenic cell lines derived from primordial stem cells are disclosed. The chondrogenic cell lines described herein are robust, can expand for >40 passages, and have site-specific purity, thus providing for compositions and methods of producing diverse cartilage types with unique molecular compositions for use in research and therapy. | 2012-07-05 |
20120171172 | Methods Of Engineering Neural Tissue - In one aspect, the invention is a method of generating a neural conduit comprising neurotrophic factors and angiogenic factors ex vivo comprising introducing cells that enhance nerve regeneration into an isolated, naturally occurring epineural sheath, thereby producing a combination. The combination is maintained under conditions in which neurotrophic factors and angiogenic factors are expressed in the epineural sheath, thereby generating a neural conduit comprising neurotrophic factors and angiogenic factors ex vivo. In another aspect, the invention is directed to neural conduits such as a neural conduit produced by the methods provided herein. In other aspects, the invention is directed to an article of manufacture. | 2012-07-05 |
20120171173 | PROCESS FOR PRODUCTION OF NATURAL KILLER CELLS - A process for producing a cell mass containing natural killer cells, characterized by involving a step of carrying out the expansion culture of a cell mass containing natural killer cells and/or cells capable of being differentiated into natural killer cells in the presence of a biological response modifier and cells that has been so treated as to lose a proliferation capability, and others. | 2012-07-05 |
20120171174 | Methods of Inducing Tissue Regeneration - Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from postmitotic tissues derived from patients with diseases allows for a characterization of pathways that have gone awry in these diseases and for screening of drugs that will ameliorate or correct the defects as a means of novel drug discovery. Also provided are kits for performing these methods. | 2012-07-05 |
20120171175 | METHODS FOR TREATING REFRACTORY INFECTIONS IN NEUTROPENIC INDIVIDUALS - The invention is based, in part, on the discovery of a novel cell-based immunotherapy that can recapitulate neutrophil functions in neutropenic individuals afflicted with a microbial infection. The therapeutic methods of the invention are broadly applicable to treat any infection in a neutropenic individual, including infections caused by bacteria, fungi, protozoa, and viruses. The methods of the invention represent a practical, rapid cell-based immunotherapy for refractory infections comprising compositions of activated, irradiated HL-60 cells. | 2012-07-05 |
20120171176 | USE OF NUTRITIONAL COMPOSITIONS INCLUDING LACTOFERRIN AND ONE OR MORE PREBIOTICS IN INHIBITING ADHESION OF PATHOGENS IN THE GASTROINTESTINAL TRACT - A method for inhibiting the adhesion of at least one pathogen in the gastrointestinal tract of a human is disclosed herein. In certain embodiments, the method involves administering to the human a nutritional composition including a fat or lipid source, a protein source, a prebiotic composition that includes galactooligosaccharide and/or polydextrose and lactoferrin produced by a non-human source. | 2012-07-05 |
20120171177 | NUTRITIONAL COMPOSITION FOR SUPPORTING BRAIN DEVELOPMENT AND FUNCTION OF TODDLERS - The present invention relates to a nutritional composition, in particular directed to toddlers and/or a weaning child, said nutritional composition comprising a protein source, a source of available carbohydrates, a lipid source, at least one probiotic microorganism, and prebiotics, wherein said lipid source comprises DHA (docosahexaenoic acid). The nutritional composition improves cognitive performance, in particular learning and memory of the child. Preferably, the composition comprises iron, zinc, vitamin D and/or sialic acid. Preferably, the composition comprises a source of phospholipids rich in DHA. | 2012-07-05 |
20120171178 | NUTRITIONAL COMPOSITION FOR SUPPORTING BRAIN DEVELOPMENT AND FUNCTION OF CHILDREN - The present invention relates to a nutritional composition, in particular directed to children of 3-6 years, said nutritional composition comprising a protein source, a source of available carbohydrates, a lipid source, at least one probiotic microorganism, and prebiotics, wherein said lipid source comprises DHA (docosahexaenoic acid) and/or ARA (arachidonic acid). The nutritional composition improves cognitive performance, in particular memory, learning comprehension, alertness, attention, concentration, processing speed, conceptual thinking, abstract thinking, verbal abilities, language comprehension, psychomotor skills, curiosity, and confident interaction with the environment. Preferably, the composition comprises one, a combination of several or all selected of the group of DHA, ARA, LA, ALA, choline, iron, iodine and folic acid. | 2012-07-05 |
20120171179 | APPARATUS, SYSTEM, AND METHOD FOR COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, OR ALLEVIATING BONE OR CARTILAGE DISEASES - The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases. The present invention discloses a method and a pharmaceutical composition comprising adipose-derived stem cells, platelet rich plasma, calcium chloride, and hyaluronic acid for the treatment, prevention, or alleviation of bone diseases, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases. | 2012-07-05 |
20120171180 | COMPOSITIONS COMPRISING AMNION DERIVED ADHERENT CELLS AND PLATELET-RICH PLASMA - Provided herein are methods of using amnion derived adherent cells, and populations of, and compositions comprising, such cells, in the modulation of an immune response. In various embodiments, the immune response is graft-versus-host disease, an allergy, asthma, or an immune-related disease or disorder, e.g., an autoimmune disease. | 2012-07-05 |
20120171181 | COMPOSITIONS AND MINIMALLY INVASIVE METHODS FOR TREATING CANCER - Methods are described for using compositions containing platelet-rich plasma for the treatment of a cancer in a variety of tissues. Particularly, treatment of brain cancer with platelet releasate is described. | 2012-07-05 |
20120171182 | METHODS AND COMPOSITIONS FOR THE TREATMENT, PREVENTION, AND ALLEVIATION OF BONE AND CARTILAGE DISEASES OR INJURIES AND HAIR LOSS - The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries. | 2012-07-05 |
20120171183 | ARTHROPODICIDAL ANTHRANILAMIDES - This invention provides a composition comprising a biologically effective amount of a compound of Formula 1, an N-oxide or an agriculturally suitable salt thereof | 2012-07-05 |
20120171184 | CELLULAR HYDRATION COMPOSITIONS - A composition interacts with a biological cell system that includes bioactive molecules with biomolecular surfaces, cellular components and water molecules with a specific density. The composition includes a biologically active component that is constructed to increase an activity of a biological cell system by increasing the hydration of one or more components of that cell system. The biologically active component may include a primary carbohydrate clathrate subcomponent that increases the H-bonded structure of water, and a secondary solute subcomponent. The biologically active component may include an inclusion complex that is made up of a clathrate component and a complex-forming compound. The clathrate subcomponent may include amyloses or cyclodextrins. There is also a beverage and a method that improves cellular hydration in an animal, such as a human. | 2012-07-05 |
20120171185 | Formulation and Method for Providing Safe, Clean, Chlorinated Recreational Water - A solid formulation for use with sodium chloride and a chlorine generator to provide safe, clean chlorinated recreational water. The formulation comprises a chlorine stabilizing agent and a phosphate remover agent. An enhanced salt comprising a chlorine stabilizing agent, a phosphate remover agent and sodium chloride is also described. The formulation and enhanced salt can also contain a metal chelating agent and a pH balancing agent. A cleaning agent may also be included. A fast dissolving sodium cyanurate compound is used for the chlorine stabilizing agent. A method, kit, and system for providing safe, clean chlorinated recreational water are also disclosed. | 2012-07-05 |
20120171186 | METHOD FOR PRODUCING A NUTRACEUTICAL COMPOSITION AND THE NUTRACEUTICAL PRODUCED BY THE METHOD - A method for producing a nutraceutical composition comprising a combination of oil soluble antioxidants derived from an edible oil and water soluble antioxidants derived from a plant extract, wherein the plant extract further provides a natural surfactant; and the nutraceutical composition produced by that method. | 2012-07-05 |
20120171187 | DEBRIDING COMPOSITION FROM BROMELAIN AND METHODS OF PRODUCTION THEREOF - The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing. | 2012-07-05 |
20120171188 | Artificial Peptidoglycan Lysing Enzymes and Peptidoglycan Binding Proteins - The present invention relates to recombinant polypeptides having the activity of binding and lysing of bacteria, comprising at least one enzymatically active domain and at least two bacterial cell binding domains. The present invention further relates to recombinant polypeptide having the activity of binding bacteria, comprising at least two bacterial cell binding domain. Further the present inventions relates to nucleic acid molecules comprising a nucleotide sequence encoding the recombinant polypeptides, vectors and host cells. | 2012-07-05 |
20120171189 | Polypeptides of Botryosphaeria Rhodina - The invention relates to functional polypeptides secreted from | 2012-07-05 |
20120171190 | METHODS FOR DIAGNOSING CHRONIC DIARRHEA THROUGH PROTEIN SECRETION ANALYSIS - Methods for diagnosing chronic diarrhea and other gastrointestinal conditions. In the methods, a sample of gastrointestinal secretions is obtained from a control group; or a group who has been diagnosed with either healthy gastrointestinal tracts or with a gastrointestinal condition, like chronic diarrhea. The control group samples are analyzed in any suitable manner to determine the levels of gastrointestinal secretions, including one or more autophagy-related proteins, cytokeratins, digestive enzymes, or other proteins. The results of the sample analysis are used to create a database containing profiles of normal and abnormal gastrointestinal secretions. As the database is created and specific secretion level abnormalities are identified, patients may be diagnosed with these abnormalities and be treated by adjusting the levels of specific secretions. Gastrointestinal samples from subsequent patients may be analyzed and compared with the database to determine which of the patients' secretion levels, if any, are abnormal. | 2012-07-05 |
20120171191 | MEGANUCLEASE VARIANTS CLEAVING THE GENOME OF A PATHOGENIC NON-INTEGRATING VIRUS AND USES THEREOF - An I-CreI variant, wherein at least one of the two 1-Cre1 monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the genome of a non-integrating virus, in particular herpes simplex virus (HSV) or Hepatitis B virus (HBV) for use in genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy as well as the treatment of a virus infection. | 2012-07-05 |
20120171192 | METHODS AND MATERIALS FOR MODULATING DEUBIQUITINASES AND UBIQUITINATED POLYPEPTIDES - This document relates to methods and materials involved in modulating deubiquitinases (e.g., USP10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided. This document also provides methods and materials for identifying agonists or antagonists of USP10 polypeptide mediated stabilization of p53 polypeptides. | 2012-07-05 |
20120171193 | Diagnostic and Treatment Methods for Characterizing Bacterial Microbiota in Skin Conditions - The present invention relates to methods for characterization of bacterial skin microbiota to provide diagnostic, therapeutic, and preventive measures for alleviating skin conditions. In certain embodiments, the invention relates to characterization of bacterial skin microbiota associated with psoriasis and related diagnostic, therapeutic, and preventive measures for alleviating psoriasis. These methods will be useful for detecting, diagnosing, and monitoring individuals who have or are at risk of certain skin conditions. | 2012-07-05 |
20120171194 | Method of Cell Differentiation and Uses Therefor in Screening, Diagnosis and Therapy - The present invention provides a method of producing non-haematopoietic cells, in particular cells having one or more properties of endothelial cells, from monocytes. A range of diagnostic and prognostic assay methods for determining whether or not a subject has atherosclerosis or vascular complication associated therewith, or a predisposition for developing atherosclerosis or complication associated therewith employing this method are provided. A range of screens to identify and isolate compositions of matter that modulate the ability of monocytes to differentiate into such non-haematopoietic cells and/or that modulate the ability of such non-haematopoietic cells to become incorporated into endothelium e.g., vascular endothelium, are also provided. | 2012-07-05 |
20120171195 | ANTI-HLA-E ANTIBODIES, THERAPEUTIC IMMUNOMODULATORY ANTIBODIES TO HUMAN HLA-E HEAVY CHAIN, USEFUL AS IVIG MIMETICS AND METHODS OF THEIR USE - Provided herein are compositions comprising antibodies immunoreactive to human leukocyte antigen E (HLA-E) and HLA Ia alleles, methods of their use, for example, as therapeutic IVIg mimetics, methods of their preparation and methods of their immunomodulatory benefits and applications. In particular embodiments provided herein are compositions and methods for treating an inflammatory condition or graft rejection. | 2012-07-05 |
20120171196 | MONOCLONAL ANTIBODIES THAT NEUTRALIZE ANTHRAX TOXINS - The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 2012-07-05 |
20120171197 | Binding members for interleukin-4 receptor alpha (IL-4Ra) - 173 - Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD. | 2012-07-05 |
20120171198 | USE OF IGG1 IMMUNOGLOBULINS AND/OR LIGANDS OF THE CD32 RECEPTOR FOR TREATING INFLAMMATORY DISEASES AND MANIFESTATIONS VIA THE MUCOSAL ROUTE - The present invention concerns the use of immunoglobulins of IgG | 2012-07-05 |
20120171199 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. | 2012-07-05 |
20120171200 | Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells - This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies. | 2012-07-05 |
20120171201 | METHODS OF TREATING HER2 POSITIVE CANCER WITH HER2 RECEPTOR ANTAGONIST IN COMBINATION WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN - The present invention relates to methods of treating a HER2 positive cancer in mammals. The present invention includes administering a HER2 antagonist in combination with a polymeric prodrug of 7-ethyl-10-hydroxycamptothecin to the mammals in need thereof. | 2012-07-05 |
20120171202 | Rage Fusion Proteins And Methods Of Use - Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C | 2012-07-05 |
20120171203 | ACTIVIN RECEPTOR-LIKE KINASE-1 COMPOSITIONS AND METHODS OF USE - Disclosed herein are methods and compositions for treating disorders associated with angiogenesis or lymphangiogenesis using ALK-1 antagonists. | 2012-07-05 |
20120171204 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS - The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention. | 2012-07-05 |
20120171205 | Galectin-Immunoglobulin Chimeric Molecules - Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers. | 2012-07-05 |
20120171206 | METHODS OF STIMULATING LIVER REGENERATION - Provided herein are methods and compositions, including pharmaceutical compositions, for stimulating liver regeneration after partial hepatectomy, massive liver resection and toxic injury, or following liver transplantation, including small-for-size liver transplantation, by inhibiting activation of complement. | 2012-07-05 |
20120171207 | DEPLETING IMMUNOSUPPRESSIVE MONOCYTES WITHIN A MAMMAL - This document provides methods and materials involved in depleting immunosuppressive monocytes (e.g., CD14 | 2012-07-05 |
20120171208 | Anti-PRO87299 Antibodies - The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease. | 2012-07-05 |
20120171209 | IMPROVED AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind (as defined herein) Interleukin-6 Receptor (IL-6R), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. In a specific aspect, the present invention provides amino acid sequences and polypeptides that are capable of binding to two or more different antigenic determinants, epitopes, parts, domains of IL-6R, also referred to as “multiparatopic” (such as e.g. “biparatopic” or “triparatopic”, etc.) amino acid sequences and polypeptides. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides, methods for preparing such amino acid sequences and polypeptides, host cells expressing or capable of expressing such amino acid sequences or polypeptides, compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 2012-07-05 |
20120171210 | METHODS AND COMPOSITIONS FOR INHIBITING C-MET DIMERIZATION AND ACTIVATION - The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met antagonist that disrupts c-met multimerization. | 2012-07-05 |
20120171211 | SERUM RESISTANCE FACTORS OF GRAM POSITIVE BACTERIA - A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection. | 2012-07-05 |
20120171212 | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE PREVENTION OF AUTOIMMUNE DISEASES - The present invention is directed to therapeutic compositions and methods for the prevention or treatment of autoimmune diseases, comprising molecules that disrupt or prevent the assembly of the trimolecular complex required for the T cell immune response comprising the autoantigen, the MHC class II molecule, and the T cell receptor implicated in the autoimmune disease. | 2012-07-05 |
20120171213 | METHOD OF TREATING TUMORS - A method of reducing the potential of pluripotent stem cells to generate teratomas in a subject is provided. | 2012-07-05 |
20120171214 | POLYPEPTIDES - The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies. | 2012-07-05 |
20120171215 | NOGO-A BINDING MOLECULES AND PHARMACEUTICAL USE THEREOF - The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant <1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system. | 2012-07-05 |
20120171216 | PALMITATED MONOCLONAL ANTIBODY - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 2012-07-05 |
20120171217 | Monoclonal Antibodies Against ANGPTL4 - Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided. | 2012-07-05 |
20120171218 | Compositions And Methods For The Therapy And Diagnosis Of Influenza - The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. | 2012-07-05 |
20120171219 | USE OF PKC-ZETA AS A BREAST CANCER TUMORIGENIC BIOMARKER AS WELL AS A TARGET FOR TREATMENT OF BREAST CANCER - The present invention provides use of protein kinase C-zeta (PKC-ζ) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer. | 2012-07-05 |
20120171220 | FURTHER USE OF PROTEIN KINASE N BETA - The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway. | 2012-07-05 |
20120171221 | BIOMARKERS FOR THE EARLY DETECTION OF AUTOIMMUNE DISEASES - Provided are methods for aiding in diagnosing autoimmune diseases in a mammal, comprising contacting a sample of tear from the mammal with an antibody that specifically binds to a first polypeptide selected from the group Ctss, Ctsh, Ctsr, Ctsw, Ctsz, Ifng, Il16ra, Il10, Il10ra, Il15, Tnfa, Apo-F, or Lcn-2 or a second polypeptide selected from the group lactoperoxidase, lactoferrin or lysozyme under conditions favoring the formation of an antibody-polypeptide complex, and determining the amount of complex formed, wherein an increased formation of antibody-first-polypeptide complex or a decreased formation of antibody-second-polypeptide complex as compared to a suitable control, indicates a likely positive diagnosis of an autoimmune disease for the mammal, thereby aiding in the diagnosis. Methods of treating the autoimmune diseases are also provided. | 2012-07-05 |
20120171222 | METHODS AND COMPOSITIONS INVOLVING NUCLEOTIDE REPEAT DISORDERS - The present invention concerns the methods and compositions involving nucleic acids with long repeat sequences. In some embodiments of the invention, there are methods for generating such a nucleic acid, and in other methods, there are methods for using such a nucleic acid to screen for candidate therapeutic compounds. Furthermore the present invention relates to methods of screening for Notch inhibitors and other substances that may be used to treat muscle loss and wasting. | 2012-07-05 |
20120171223 | HIGH AFFINITY ANTIBODIES THAT NEUTRALIZE STAPHYLOCOCCUS ENTEROTOXIN B - This invention provides antibodies that specifically bind and neutralize | 2012-07-05 |
20120171224 | Anti-ADDL Antibodies and Uses Thereof - The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42. | 2012-07-05 |
20120171225 | Diagnostic Method for Predicting the Risk of Cancer Recurrence Based on Histone Macroh2A Isoforms - The present invention relates to a method for diagnosing the risk of cancer recurrence in a mammalian patient, comprising detecting the expression of macroH2A1.1 and/or macroH2A2 in a biological sample obtained from said patient, wherein a low or reduced expression of said macroH2A1.1 and/or macroH2A2 is indicative for an increased risk of cancer recurrence in said patient. The present invention is further directed at improved methods for treating cancer, in particular breast and/or lung cancer, based on said diagnostic method. | 2012-07-05 |
20120171226 | ANTIBODIES TO HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN - The present disclosure relates to anti-high molecular weight melanoma associated antigen (HMW-MAA) antibodies which bind to human HMW-MAA. Such antibodies may be used to treat diseases or disorders characterized by expression of HMW-MAA including cancer, for example, melanoma, basal cell carcinoma, ALL or AML. | 2012-07-05 |
20120171227 | PRO-DRUG COMPLEXES AND RELATED METHODS OF USE - The present invention provides methods, compositions and applications for efficient, site-specific drug delivery using pro-drug complexes comprising therapeutic agents and one or more functional groups (e.g., imaging agents, targeting agents, and trigger agents). In particular, the present invention relates to pro-drug complexes comprising one or more functional groups conjugated with a therapeutic agent (e.g., a chemotherapeutic agent), methods of synthesizing the same, as well as systems and methods utilizing the therapeutic and diagnostic compositions (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, etc.)). | 2012-07-05 |
20120171228 | ANTI-CANCER REGIMEN - The invention comprises the administration of an amount of honokiol (HNK) and Modified Citrus Pectin (MCP) or similar pectin or alginate in amounts synergistic to inhibit cancer. The inhibition can be of the formation of cancer, the progression of a cancer already formed, or the transformation of a primary cancer to a metastatic one. HNK and MCP appear to be synergistic across their effective ranges, and the synergy may be due in part to the binding of galectin-3 on the surface of tumor cells by MCP, which better presents the cell for the cytotoxic effects of HNK. Compositions of matter which combine the two agents, HNK and MCP, in synergistic amounts intended for daily administration are also contemplated. The administration of MCP and HNK may be combined with the administration of conventional anti-cancer therapeutics. | 2012-07-05 |
20120171229 | SYNTHETIC NANOCARRIERS WITH REACTIVE GROUPS THAT RELEASE BIOLOGICALLY ACTIVE AGENTS - This invention relates to compositions, and related compounds and methods, of conjugates of synthetic nanocarriers, or components thereof, and biologically active agents, such as immunomodulatory agents, antigens, anticancer agents or antiviral agents. The biologically active agents are released from the synthetic nanocarriers in the presence of a reducing agent or by reaction with a thiol. | 2012-07-05 |
20120171230 | ORAL VACCINES PRODUCED AND ADMINISTERED USING EDIBLE MICRO-ORGANISM - The anti-pathogen vaccine of the present invention is produced in recombinant bacteria and/or transgenic plants and then administered through standard vaccine introduction method or through the oral administration. A DNA sequence encoding for the expression of an antigen of a pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a bacterial or transgenic plant. Preferably, a foreign gene is expressed in a portion of the plant or bacteria, and all or part of the antigen expressing plant or bacteria used for vaccine administration. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, or the bacteria administered orally. The present invention also provides a method of using genetically modified microorganisms generally recognized to be edible and/or harmless to animals or humans when ingested, such as lactic acid bacteria, including | 2012-07-05 |
20120171231 | USE OF NUTRITIONAL COMPOSITIONS INCLUDING LACTOFERRIN IN STIMULATING IMMUNE CELLS - The present disclosure relates to the use of nutritional compositions including lactoferrin produced by a non-human source in stimulating innate immune cells, such as macrophages, neutrophils, and dendritic cells. | 2012-07-05 |
20120171232 | IN VIVO EFFICACY OF NY-ESO-1 PLUS ADJUVANT - The invention relates to the discovery that administration of NY-ESO-1 protein, in combination with a saponin based adjuvant leads to an unexpectedly strong immune response against NY-ESO-1 expressing cells. Preferably, the combination is administered intramuscularly. | 2012-07-05 |
20120171233 | PEPTIDE INHIBITORS FOR MEDIATING STRESS RESPONSES - The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides. | 2012-07-05 |
20120171234 | Novel Biologically Active Peptides and their New Uses - Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual. | 2012-07-05 |
20120171235 | MARKERS OF XMRV INFECTION AND USES THEREOF - The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. Additionally, the invention relates to specific XMRV antigens capable of inducing an immunogenic response as well as XMRV-related nucleic acids having significant diagnostic, screening, and therapeutic utilities. | 2012-07-05 |
20120171236 | IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE - The published genomic sequence of | 2012-07-05 |
20120171237 | RECOMBINANT CHIMERIC ANTIGENS FOR DIAGNOSIS AND PREVENTION OF SCRUB TYPHUS - Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as Karp, Kato (Ktr56), Gilliam (Gmr56), and TA763 (TAr56). The invention is useful for detecting prior exposure to a number of strains of scrub typhus, based on the strength of reaction toward the chimeric protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects against heterologous infections. | 2012-07-05 |
20120171238 | S. AUREUS ALLERGEN - The invention discloses the use of a protein with an amino acid sequence according to SEQ. ID. NO. 1 or a naturally occurring fragment or variant thereof for identifying infections with | 2012-07-05 |
20120171240 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS - The invention provides conjugates comprising an immune co-stimulatory polypeptide and an antigen or infectious agent. The conjugates are useful for generating or enhancing an immune response against the antigen or infectious agent. The invention also provides immune cells modified with a conjugate that are useful for generating or enhancing an immune response to an antigen or infectious agent. The invention also provides immunostimulatory moieties comprising an immune co-stimulatory polypeptide that are useful for stimulating an immune response. The invention also provides immunotherapy methods and methods of treating or preventing infections. | 2012-07-05 |
20120171241 | ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE - The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers). The method can be used to analyse total and free saccharide in conjugate vaccines and simplifies quality control of vaccines containing capsular saccharides from multiple serogroups. | 2012-07-05 |
20120171242 | Modified Antibody - Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules. | 2012-07-05 |
20120171243 | METHOD OF PREPARING LIVE VIRAL VACCINES BY GENETIC ENGINEERING OF VIRAL GENOME - Disclosed is an attenuation method of an influenza virus, that is, a reassortant virus and a preparation method thereof. The disclosed reassortant virus has, in a ratio of 6:2, genes encoding a recombinant non-toxic protein and a wild type non-toxic protein, and genes encoding toxic proteins, HA (hemagglutinin) and NA (neuraminidase), of an influenza virus, the recombinant non-toxic protein consisting of a substituted caspase recognition sequence without a change of a protein size within the wild type non-toxic protein of the influenza virus. The disclosed attenuated influenza virus shows a high attenuation without a reduction of productivity in a fertilized egg. Accordingly, the method can be used as an economically efficient live vaccine preparation method which has both safety and efficiency and can use a fertilized egg as a production system. Also, since a protein is not removed or modified during attenuation, the method can be used in combination with a conventional attenuated vaccine preparation technology such as cold-adaptation. | 2012-07-05 |
20120171244 | MUCOSAL BOOSTING FOLLOWING PARENTERAL PRIMING - Mucosal immunization using one or more antigens following parenteral administration of the same or different antigens is described. | 2012-07-05 |
20120171245 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 2012-07-05 |
20120171246 | IMMUNIZATION TO REDUCE NEUROTOXICITY DURING TREATMENT WITH CYTOLYTIC VIRUSES - Methods for protecting the brain and other tissues from virus-associated toxicity are provided. Patients are treated with a first immunizing virus prior to administration of a second, therapeutic cytolytic virus. The immunizing virus is preferably administered peripherally, and initiates an adaptive immune response that is sufficient to reduce or prevent the cytovirulence and inflammation caused by the therapeutic virus. The immunizing virus is administered one or more times, preferably at least twice, before administration of the therapeutic virus. The therapeutic virus can be the same virus as the immunizing virus, or a mutant or variant thereof. Preferably the therapeutic virus is an attenuated virus with reduced virulence compared to the immunizing virus. | 2012-07-05 |
20120171247 | NOVEL PROTEINS WITHIN THE TYPE E BOTULINUM NEUROTOXIN COMPLEX - The invention features a polypeptide complex synthesized by bacteria of the genus | 2012-07-05 |
20120171248 | COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS - Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more | 2012-07-05 |
20120171249 | COMPOSITIONS FOR INACTIVATING PATHOGENIC MICROORGANISMS, METHODS OF MAKING THE COMPOSITIONS, AND METHODS OF USE THEREOF - Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided. | 2012-07-05 |
20120171251 | SHEET-FORM PREPARATION AND METHOD FOR PRODUCING THE SAME - The present invention provides a sheet-form preparation that can be easily dissolved intraorally, allows the dissolution time thereof to be easily controlled, and can stably contain an allergenic protein from cedar pollen. | 2012-07-05 |
20120171252 | OIL-IN-WATER EMULSION OF MOMETASONE AND PROPYLENE GLYCOL - Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, propylene glycol and water and the weight ratio between the propylene glycol and water contained in the oil-in-water emulsion is from 1:1 to about 1:3. | 2012-07-05 |
20120171253 | Fibromodulin Peptide - Embodiments of the present invention provide a fibromodulin (FMOD) peptide (FMOD-P), a composition and a formulation comprising a FMOD-P, optionally with a TGF-β isoform, or comprising FMOD with a TGF-β isoform. The present invention also provides methods of making and using the FMOD-P, composition, or formulation. | 2012-07-05 |
20120171254 | Process and Apparatuses for Preparing Nanoparticle Compositions with Amphiphilic Copolymers and Their Use - This invention discloses a process for making nanoparticles of amphiphilic copolymers by flash precipitation. Nanoparticles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in a nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers. Furthermore, the resulting particles exhibit sufficient stability for post processing as desired. The invention also discloses two apparatuses for the production of nanoparticles of amphiphilic copolymers by flash precipitation. | 2012-07-05 |
20120171255 | SUBSTRATE IMPREGNATED WITH SPRAYED CLAY, AND METHOD FOR MANUFACTURING SAME - The invention relates to the production of a clay-impregnated substrate ( | 2012-07-05 |
20120171256 | ELECTROSPUN SILK MATERIAL SYSTEMS FOR WOUND HEALING - The present invention relates to the processes of preparing silkfibroin/polyethylene oxide blended materials, and the resulting materials thereof, which are suitable for biomedical applications such as wound healing. In particular, the electrospun silk fibroin/PEO mats with a silk:PEO blend ratio of 2:1 to 4:1, treated with controlled evaporation, constraint-drying techniques, and/or alcohol treatment, and/or PEO extraction, demonstrate suitable physical and biofunctional properties, such as fiber structure, topography, absorption, water vapor transmission rates, oxygen permeation, and biodegradability, relevant to biomaterial systems with utility for wound dressings. | 2012-07-05 |
20120171257 | Cell-guiding fibroinductive and angiogenic scaffolds for periodontal tissue engineering - Disclosed are methods for producing cell-guiding fibroinductive and angiogenic tissue engineering scaffolds composed of biodegradable and biocompatible natural biopolymers, synthetic polymers and/or their combination, incorporating growth and differentiation factors, growth hormone and chemoattractants, with interconnected pores and channels-containing microarchitecture inducing the regenerative cell migration, adhesion, proliferation and differentiation from the healthy tissues surrounding the periodontal defects, thereby facilitating the functional periodontal tissue regeneration. The methods for the application of the cell-guiding fibroinductive and angiogenic scaffolds in the surgical treatment of periodontal tissue defects resulted from destructive periodontal diseases are also provided. | 2012-07-05 |
20120171258 | Modular Assembly of Tissue Engineered Constructs - Scaleable, vascularised tissue constructs that are composed of a multiplicity of cell containing, discrete and separable modules, methods of fabricating same and uses thereof. The tissue construct is a tissue substitute used in tissue transplantation or substitution or for the purpose of in vitro mimic of normal tissue. | 2012-07-05 |
20120171259 | ORALLY ABSORBED PHARMACEUTICAL FORMULATION AND METHOD OF ADMINISTRATION - A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound selected from the group comprising an alkali metal alkyl sulfate and a polyoxyethylene sorbitan monooleate, (c) a block copolymer of polyoxyethylene and polyoxypropylene, (d) at least one additional micelle-forming compound, and (e) a suitable solvent. The invention also provides a metered dose dispenser (aerosol or non-aerosol) containing the present formulation and a method of administering insulin using the metered dose dispenser comprising administering split doses of a formulation containing insulin before and after each meal. | 2012-07-05 |
20120171260 | Stent And Delivery System With Reduced Chemical Degradation - Stents and delivery systems with reduced chemical degradation and methods of sterilizing the same are disclosed. | 2012-07-05 |
20120171261 | FORMULATIONS OF WATER INSOLUBLE OR POORLY WATER SOLUBLE DRUGS IN LIPIDATED GLYCOSAMINOGLYCAN PARTICLES AND THEIR USE FOR DIAGNOSTICS AND THERAPY - The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery. | 2012-07-05 |
20120171262 | PHARMACEUTICAL FORMULATIONS - The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. | 2012-07-05 |
20120171263 | Oil-In-Water Nanoemulsion Containing Brazil Nut Oil, As Well As Cosmetic Composition And Cosmetic Product Comprising Same And Use Of Said Nanoemulsion - The present invention refers to an oil-in-water nanoemulsion comprising Brazil nut oil and an emulsifying system for cosmetic use, particularly for hair care. The emulsifying system comprises at least one non-ionic surfactant and at least one cationic component selected from a cationic surfactant and a cationic polymer. Another objective of the present invention is cosmetic compositions and cosmetic products that comprise a nanoemulsion characterized above. | 2012-07-05 |
20120171264 | Granulated Dry Cleanser For The Care Of Keratinous Substrates - Described herein is a granulated dry composition comprising at least one non-elastomeric polyorganosiloxane, agglomerated onto solid carrier particles. The granulated dry compositions can be used as a dry cleanser for keratinous substrates with high speed of absorption of body fluids together with improved sensory feel and release of care agents. | 2012-07-05 |
20120171265 | SILK FIBROIN HYDROGELS AND USES THEREOF - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices. | 2012-07-05 |
20120171266 | COSMETIC COMPOSITIONS AND METHODS OF MAKING AND USING THE COMPOSITIONS - Cosmetic compositions which, when applied to the skin, mask skin imperfections and provide more uniform skin tone are described. The compositions can be formulated to address the needs of users having a specific skin tone. The compositions include one or more pigments (e.g., iron oxides) and may also include reflective particles such as mica coated with iron oxide and/or titanium dioxide. The compositions can be oil-in-water emulsions comprising a discontinuous oil phase dispersed in a continuous aqueous phase. The compositions can also include emollients, one or more skin sheen additives, a film former (e.g., polycyclopentadiene) and isohexadecane. Compositions formulated for lighter skin tones can include one or more sunscreen agents. The compositions can be formulated to have high color transfer resistance. Methods of making the compositions and methods of treatment comprising applying the compositions to the skin are also described. | 2012-07-05 |
20120171267 | Durable Antimicrobial Composition - The present invention relates to compositions having durable antimicrobial activity. The compositions include a carbonate/bicarbonate salt of a quaternary ammonium cation, an organic acid, hydrogen peroxide and a cationic polymer. The cationic polymer includes either a (3-acrylamidopropyl)trimethylammonium chloride monomer or a [2-(acrylolyoxy)ethyl]trimethylammonium chloride monomer. The cationic polymer also includes another monomer selected from a polar, water-soluble monomer, a hydrophobic, silicone-containing monomer or mixtures of both types of monomers in combination with one of the trimethylammonium chloride monomers. | 2012-07-05 |
20120171268 | DISPENSER COMPRISING A POLYESTER MEMBRANE FOR CONTROL OF MITES IN BEE HIVES - The present invention is related to a dispenser, which is filled with a gel comprising a C1 to C10 carboxylic acid and a thickener, comprising a polyester membrane. The invention further relates to said gel. It also relates to s method for preparing said dispenser, comprising a) mixing C1 to C10 carboxylic acid and the thickener, and b) filling the mixture of step a) into the dispenser. The invention further relates to a method for the control of mites in bee hives comprising putting said dispenser inside or near a bee hive. It also relates to a use of the dispenser or the gel for the control of mites or of nosema in agricultural, industrial or domestic environment. | 2012-07-05 |
20120171269 | Anti-microbial articles for land vehicles, aircraft and marine craft, and method of manufacturing and using same - Nanoparticles such as nanosilver or nanocopper are used for the construct of anti-microbial articles and accessories for vehicles, trains, and/or airplanes. The anti-microbial articles include a distal section, proximal section and a primary section. The primary section further comprises nanosilver or nanocopper. In one embodiment the nanoparticles comprise a plurality of nanosilver fibers braided, woven or otherwise interwoven to form at least a portion of the primary section. Alternatively, the nanosilver is comprised of a coating over the primary section. The entire article may include the nanosilver composite. The anti-microbial article for vehicles, train, and/or airplanes includes steering wheels, steering wheel covers, gear shifts, gear shift covers, head rests, head rest covers, seats, seat covers, infant seats, infant seat covers, rugs or mats, neck pillows, door handles, door handle covers and travel blankets. Advantageously, the antimicrobial article provides a sanitary environment that kills bacteria and retards bacteria growth. | 2012-07-05 |
20120171270 | DUAL ACTION ORGANIC FORMULATION TO CONTROL TWO STAGES OF INSECT PESTS - The present invention discloses systems and methods for controlling arthropod populations. The systems include a polymeric substrate, a semiochemical that is reactive upon an adult-stage arthropod, and an insecticide that is toxic to an immature-stage arthropod. The semiochemical may be a sex pheromone that disrupts mating behavior of the adult-stage arthropod. The insecticide may be a per os insecticide that only affects the immature-stage arthropod. The arthropod to be controlled may be gypsy moths, in which case the semiochemical may be disparlure and the insecticide may be spinosad. Further disclosed are methods for preparing systems for use in controlling arthropod populations. | 2012-07-05 |
20120171271 | ANTIMICROBIAL MATERIAL FOR WATER STERILIZATION - The present invention relates to an antimicrobial material consisting of particles comprising an antimicrobial agent (A) and a carrier (B), wherein: the antimicrobial material is a granular material; at least 90% w/w of the particles have a particle size in the range of from 1.0 mm up to and including 8.0 mm measured according to the method DIN 66165-1/-2; at least 90% w/w of the particles have an aspect ratio R, equal to or lower than 8; the antimicrobial agent (A) comprises elemental silver nanoparticles; the antimicrobial agent (A) is present in an amount in the range of from 0.001% w/w up to and including 2% w/w on antimicrobial material; the carrier (B) is a polymer comprising a polyamide; the carrier (B) is present in an amount in the range of from 98% w/w up to and including 99.999% w/w on antimicrobial material. The invention further relates to an article comprising the granular antimicrobial material, a device comprising the granular antimicrobial material or the article. The invention also relates to a process for preparing the granular antimicrobial material and use of the granular antimicrobial material or an article or a device comprising the granular antimicrobial material in water treatment systems/appliances, water filters, swimming pools, whirlpools, water supply containers, water storage and for treatment of drinking water. | 2012-07-05 |
20120171272 | STABILIZED BIOCIDAL DISPERSION VIA SUB-MICRONIZED CARRIER PARTICLES, PROCESS FOR MAKING THE SAME AND COMPOSITION THEREOF - A stabilized biocidal dispersion comprising a biocide coated or adsorbed onto stable sub-micron carrier particles and wherein sub-micronized particles are stabilized by additives having polar moieties, hydrophobic and hydrophilic segments. The sub-micron particles are selected from metal oxides like zinc oxide, titanium dioxide, cerium dioxide and silica, alumina, minerals, clays, stilbene and sub-micron carbons. Exemplary biocides include carbamates, isothiazolones, pyrithione chelates and/or trizoles. Also disclosed is a process for preparing stabilized sub-micronized carrier particles. | 2012-07-05 |